Literature DB >> 25709638

The relationship between clinicobiochemical markers and depression in women with polycystic ovary syndrome.

Mohammad Ehsan Rahiminejad1, Amirhossein Moaddab2, Soghra Rabiee3, Farzaneh Esna-Ashari4, Shiva Borzouei5, Seyyed Mohammad Hosseini1.   

Abstract

BACKGROUND: Previous studies have demonstrated that clinical features of Polycystic ovary syndrome (PCOS) are associated with a lower degree of health, self, and sex satisfaction.
OBJECTIVE: Our study aimed to investigate possible associations between depression and different clinicobiochemical markers of PCOS.
MATERIALS AND METHODS: In a cross-sectional analytic study, 120 PCOS women aged 18-45 yr, were enrolled. Beck Depression Inventory was used to assess depression. Also, all participants underwent biochemical studies. Individuals with 15 points and more in Beck test were referred to a psychiatrist to participate in a complementary interview for the diagnosis of depression based on Diagnostic and Statistical Manual of Mental Disorders IV (DSMIV-TR) criteria.
RESULTS: Among the study participants, 82 women (68.3%) were non-depressed, and 38 patients (31.7%) had some degrees of depression. According to the psychiatric interview, 10 patients (8.3%) had major depression, 22 patients (18.3%) had minor depression and 6 patients (5%) had dysthymia. We failed to show any significant difference in body mass index, hirsutism, infertility, serum total testosterone, lipid profile, and the homeostasis model assessment of insulin resistance (HOMA-IR) between depressed and non-depressed subjects (p>0.05). Using Spearman correlation, we did not find a positive correlation between BDI scores and clinicobiochemical markers for all PCOS subjects (-0.139≤r≤+0.121, p>0.05).
CONCLUSION: In spite of high rate of depression in women with PCOS, there was no significant association between Clinicobiochemical Markers and depression.

Entities:  

Keywords:  Complication; Depression; Hirsutism; Obesity; Polycystic ovary syndrome

Year:  2014        PMID: 25709638      PMCID: PMC4330661     

Source DB:  PubMed          Journal:  Iran J Reprod Med        ISSN: 1680-6433


Introduction

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age, affecting 4-18% of these women (1, 2). It has significant clinical and biochemical sequelae, including reproductive features (such as infertility, hyperandrogenism, and hirsutism) and metabolic derangements (such as obesity, insulin resistance, impaired glucose tolerance, type II diabetes mellitus, and adverse cardiovascular risk profiles) (3). In addition, women with PCOS have a greater degree of mood dysfunction, psychiatric disorders and emotional distress than women without PCOS (4, 5). A recent systematic review and meta-analysis of 12 published comparative studies between women with PCOS and healthy controls revealed higher depression and anxiety scores in patients with PCOS, is associated with Body Mass Index (BMI) (6). In addition, previous studies have demonstrated that the clinical features associated with PCOS, such as physical appearance (hirsutism, obesity and acne), menstrual abnormalities (oligomenorrhoea) and infertility are associated with a lower degree of satisfaction with health, self, and sex affecting Health Related Quality of Life (HRQoL) (7, 8). Despite this proved issue, the association between infertility, biochemical hyperandrogenism, hirsutism, acne, body image and depression is still controversial (9). Depression is a major public health problem in both developed and developing countries and a leading cause of disability and global disease burden (10, 11). Surveys in the United States have shown that major depressive disorder (MDD) based on the Diagnostic and Statistical Manual IV (DSM-IV) affects approximately 14.8 million American adults or about 12-14% of the 18-44 year-old American women in a given year (12, 13). Furthermore, it is well known that MDD is more prevalent in women than in men (14). In Iran, based on a systematic review the prevalence of MDD among Iranian adults is 4.1% and women are more likely to have MDD, approximately 1.95 times more than men (15). In the literature, depression in women with PCOS has a wide range of prevalence rates, reported between 14% and 64% (16). In Shakerardekani's study the prevalence of depression in PCOS women was 45% according to Beck Depression Inventory (BDI) (17). It seems that social and cultural differences and various assessment methods have led to this wide range of prevalence rates. This shows the necessity for further studies in different ethnic groups worldwide (16). The aim of this study was to investigate the rate of depression among women with PCOS, and to analyze associations between depression and different clinicobiochemical markers of PCOS.

Results

Among all participants, 82 (68.3%) patients were non-depressed, and 38 (31.7%) patients had various degrees of depression. Based on the Beck Inventory scores, 28 (23.3%) patients suffered from mild depression, 9 (7.5%) had moderate depression, and one patient (0.8%) had severe depression. The mean age of individuals in the non-depressed and depressed patients were 23.6±4.7 and 24.8±4.6 year, respectively, with no significant differences (p=0.192). Based on psychiatric interview, 10 patients (8.3%) had MDD, 22 (18.3%) had minor depression and 6 patients (5%) suffered from dysthymia. There was no difference in the frequency of depression relative to marital status. Of the 82 non-depressed patients 41 (50%) were married and 41 (50%) were single. Of 38 depressed patients 17 (44.7%) were married and 21 (51.3%) were single (p=0.591). The mean BMI in non-depressed patients was 24.8±4.3, which was not significantly different from that in depressed patients (24.96±5.01) (p=0.177). The assessment for hirsutism showed that among 38 depressed patients, 23 (60.5%) and of 82 patients without depression 38 patients (46.3%) had hirsutism. The present study failed to show any significant differences in serum TT, TG, total cholesterol, LDL, HDL and HOMA-IR between depressed and non-depressed patients. In addition, these measurements revealed no differences between patients with mild and moderate depression. Table I presents a comparison of the clinical and biochemical parameters among depressed and non-depressed patients. Investigation of infertility in patients showed that 28 (34.1%) of non-depressed patients suffered from infertility, 11 (13.4 %) had been fertilized and 43 (52.5%) had unknown fertility status. Among depressed patients, 7 (18.4%), 8 (21.1%) and 23 (60.5%) patients had infertility, had been fertilized and had unknown fertility status, respectively.
Table I

Comparison of demographic and clinicobiochemical markers between depressed and non-depressed patients based on Beck Inventory scores

No depression (n=82) Depression (n=38) p-value
Beck7.89 ± 4.3425.45 ± 8.83
Age (yr)23.6 ± 4.724.8 ± 4.60.192a
Testosterone (ng/mL)0.66 ± 0.180.73 ± 0.160.634a
TG (mg/dl)132.70 ± 59.96136.89 ± 49.810.739a
LDL (mg/dL)106.54 ± 21.97112.58 ± 23.500.554 a
HDL (mg/dL)44.11 ± 6.9544.11 ± 6.540.359 a
Cholesterol (mg/dL)170.37 ± 21.66174.63 ± 22.910.366 a
HOMA-IR1.40 ± 0.531.34 ± 0.510.746 a
BMI (kg/m2) 24.8 ± 4.324.9 ± 5.10.177 a
Marital status
Married41 (50%)17 (44.7%)0.591 b
Single41 (50%)21 (55.3%)
Infertile
Yes28 (34.1%7 (18.4%)0.177 b
No11 (13.4%)8 (21.1%)
Unknown43 (52.5%)23 (60.5%)
Hirsutism
Yes38 (46.3%)23 (60.5%)0.148 b
No44 (53.7%)15 (39.5%)

TG: triglycerides

LDL: low-density lipoprotein

HDL: high-density lipoprotein

BMI: Body Mass Index

HOMA-IR: homeostasis model assessment of insulin resistance ( fasting glucose (μU/L)× fasting insulin (mmol/L)/22.5)

Hirsutism (Modified Ferriman-Galwey score ≥ 6)

Student’s t test

chi-squared test

No differences were found in infertility prevalence based on depression status in women with PCOS. All the individuals were asked about their main concern for health issues related to their disease; 42 patients (35%) considered hirsutism as their most important concern, while 27 patients (22.5%) and 44 patients (36.7%) believed obesity and infertility were their main concerns, respectively. Using Spearman correlation, we did not find a positive correlation between BDI scores and clinicobiochemical markers for all PCOS subjects (-0.139≤r≤+0.121, p>0.05) (Table II).
Table II

Spearman correlations between BDI and clinicobiochemical markers of PCOS

Testosterone LDL TG HDL Cholesterol BMI HOMA-IR
BDI Score
Correlation Coefficient0.1210.1080.0720.0320.0640.012-0.139
Sig. (2-tailed) *0.1890.2390.4350.7310.4850.8990.131

TG: triglycerides

LDL: low-density lipoprotein

HDL: high-density lipoprotein

BMI: Body Mass Index

BDI: Beck Depression Inventory

HOMA-IR: homeostasis model assessment of insulin resistance

Correlation is significant at the 0.05 level (2-tailed).

Comparison of demographic and clinicobiochemical markers between depressed and non-depressed patients based on Beck Inventory scores TG: triglycerides LDL: low-density lipoprotein HDL: high-density lipoprotein BMI: Body Mass Index HOMA-IR: homeostasis model assessment of insulin resistance ( fasting glucose (μU/L)× fasting insulin (mmol/L)/22.5) Hirsutism (Modified Ferriman-Galwey score ≥ 6) Student’s t test chi-squared test Spearman correlations between BDI and clinicobiochemical markers of PCOS TG: triglycerides LDL: low-density lipoprotein HDL: high-density lipoprotein BMI: Body Mass Index BDI: Beck Depression Inventory HOMA-IR: homeostasis model assessment of insulin resistance Correlation is significant at the 0.05 level (2-tailed). Flow diagram of patients through the study protocol.

Discussion

The present study was performed to assess depression in patients with PCOS. We aimed to describe the signs and symptoms of PCOS differences between depressed and non-depressed subjects, respectively. In the present study, the rate of MDD was 8.3%, which is lower than that in other studies (6, 21, 22). On the other hand, the overall rate of depression in our study was lower than previous study in Iran measured, by a similar method (31.7% vs. 45%) (17). Although these results show that the rate of MDD among PCOS patients with MDD in the general population has more than doubled. (4.1% vs. 8.3%) (15). This result suggests that attention to psychological aspects should be considered in PCOS patients. Depression and clinical manifestations of PCOS Obesity, especially abdominal obesity, is a common characteristic of these patients, which compromises the patient's appearance and results in many esthetic problems for them (23). However, despite the variety of information about the impact of obesity on psychological stress and depression, in the present study the mean BMI did not differ in non-depressed and depressed patients. Our findings do not support the previous studies that considered obesity as a risk factor for depression in patients with PCOS (24, 25). Along with this study, some studies found no relationship between depression and obesity in patients with PCOS (6, 22). In the present study, hirsutism, as a clinical manifestation of PCOS, was not significantly different in depressed and non-depressed patients, inconsistent with some previous studies which considered hirsutism concomitant with higher grade of depression (26). In this study, infertility rate was 29.2%, and there was no significant association between infertility and depression in participants. It is worth mentioning that a great number of patients (55%) were not aware of their own ability to conceive, which might have resulted in misjudgment. Consistent with this study, Hollinrake et al found that on analysis of the PCOS group alone, similar numbers of depressed and non-depressed PCOS women reported a history of infertility (20). We found that PCOS patients considered infertility as the most important concern (36.7%). Since infertility treatment in these patients is feasible, with a systematic treatment and reassurance, the patient can reduce much of the concern. Depression and biochemical markers of PCOS To evaluate differences between depressed and non-depressed PCOS patients, we measured biochemical markers and compared them between the two groups. The relationship between depression and insulin resistance, as one of the leading factors in the pathophysiology of PCOS, has been examined in a few studies which have shown conflicting results (26-28). Depression is associated with increased cortisol levels, increased sympathetic nervous system activity and decreased serotonin in the central nervous system. These features are also associated with insulin resistance (27). If depression affects insulin resistance, people with insulin resistance (e.g. patients with PCOS), who simultaneously suffer from depression, are exposed to metabolic condition changes which results in type II diabetic development. Timely and robust treatment of depression may be a good and appropriate strategy to prevent or reduce development of insulin resistance (27, 28). We found no significant differences in insulin resistance between the two groups. However, it seems that evaluation of relationship between insulin resistance and psychological stress in patients with PCOS needs to be investigated further. Women with PCOS may have clinical presentations or biochemical evidence of hyperandrogenism. Several studies have shown a correlation between the severity of depression and serum androgens (29-31). Despite absence of significant differences between the two groups, in this study the mean serum testosterone level in patients with depression was slightly higher than non-depressed patients (0.74 vs.0.67). The results of the present study are similar to those reported by Hollinrake et al (20). Lipid profiles, including total cholesterol, HDL, LDL and TG, were also compared and no differences were found between depressed and non-depressed PCOS patients.

Conclusion

In spite of high rate of depression in women with PCOS, we failed to show an association between any of the clinicobiochemical markers and depression. However, like Farrell and Antoni, we emphasize that the physiological and psychological factors among women with PCOS are strongly interrelated and suggest that in medical management of PCOS both physiological and psychological approaches should be used (4).
  29 in total

1.  Testosterone, androstenedione and dihydrotestosterone concentrations are elevated in female patients with major depression.

Authors:  B Weber; S Lewicka; M Deuschle; M Colla; I Heuser
Journal:  Psychoneuroendocrinology       Date:  2000-11       Impact factor: 4.905

2.  Associations between depressive symptoms and insulin resistance: the Hoorn Study.

Authors:  M C Adriaanse; J M Dekker; G Nijpels; R J Heine; F J Snoek; F Pouwer
Journal:  Diabetologia       Date:  2006-10-26       Impact factor: 10.122

3.  A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.

Authors:  E Diamanti-Kandarakis; C R Kouli; A T Bergiele; F A Filandra; T C Tsianateli; G G Spina; E D Zapanti; M I Bartzis
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

Review 4.  Mood and anxiety disorders in women with PCOS.

Authors:  Anuja Dokras
Journal:  Steroids       Date:  2011-12-09       Impact factor: 2.668

5.  The relationship between clinico-biochemical characteristics and psychiatric distress in young women with polycystic ovary syndrome.

Authors:  E Adali; R Yildizhan; M Kurdoglu; A Kolusari; T Edirne; H G Sahin; B Yildizhan; M Kamaci
Journal:  J Int Med Res       Date:  2008 Nov-Dec       Impact factor: 1.671

6.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

7.  Global burden of depressive disorders in the year 2000.

Authors:  T B Ustün; J L Ayuso-Mateos; S Chatterji; C Mathers; C J L Murray
Journal:  Br J Psychiatry       Date:  2004-05       Impact factor: 9.319

8.  The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria.

Authors:  Wendy A March; Vivienne M Moore; Kristyn J Willson; David I W Phillips; Robert J Norman; Michael J Davies
Journal:  Hum Reprod       Date:  2009-11-12       Impact factor: 6.918

9.  Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study.

Authors:  Angela Kerchner; Whitney Lester; Scott P Stuart; Anuja Dokras
Journal:  Fertil Steril       Date:  2008-02-04       Impact factor: 7.329

10.  Epidemiology of major depressive disorder in iran: a systematic review and meta-analysis.

Authors:  Behnam Sadeghirad; Ali-Akbar Haghdoost; Masoumeh Amin-Esmaeili; Esmaeil Shahsavand Ananloo; Padideh Ghaeli; Afarin Rahimi-Movaghar; Elham Talebian; Ali Pourkhandani; Ahmad Ali Noorbala; Esmat Barooti
Journal:  Int J Prev Med       Date:  2010
View more
  8 in total

1.  Psychological Experiences of Adolescent Girls with Polycystic Ovary Syndrome: A Qualitative Study.

Authors:  Maryam Ekramzadeh; Leila Hajivandi; Mahnaz Noroozi; Firoozeh Mostafavi
Journal:  Iran J Nurs Midwifery Res       Date:  2020-06-17

Review 2.  Depression and serum low-density lipoprotein: A systematic review and meta-analysis.

Authors:  Jane E Persons; Jess G Fiedorowicz
Journal:  J Affect Disord       Date:  2016-07-19       Impact factor: 4.839

3.  Comparison of prevalence of periodontal disease in women with polycystic ovary syndrome and healthy controls.

Authors:  Mohammad Ehsan Rahiminejad; Amirhossein Moaddab; Hassan Zaryoun; Soghra Rabiee; Arta Moaddab; Amin Khodadoustan
Journal:  Dent Res J (Isfahan)       Date:  2015 Nov-Dec

4.  Association between severity of depression and clinico-biochemical markers of polycystic ovary syndrome.

Authors:  Behnaz Enjezab; Maryam Eftekhar; Akram Ghadiri-Anari
Journal:  Electron Physician       Date:  2017-11-25

Review 5.  Polycystic Ovary Syndrome, Affective Symptoms, and Neuroactive Steroids: a Focus on Allopregnanolone.

Authors:  Lindsay R Standeven; Elizabeth Olson; Nicole Leistikow; Jennifer L Payne; Lauren M Osborne; Liisa Hantsoo
Journal:  Curr Psychiatry Rep       Date:  2021-04-21       Impact factor: 5.285

6.  Depressive and Anxiety Symptom Assessment in Adults with Polycystic Ovarian Syndrome.

Authors:  Wadha K Almeshari; Alanoud K Alsubaie; Reham I Alanazi; Yara A Almalki; Nazish Masud; Sami H Mahmoud
Journal:  Depress Res Treat       Date:  2021-04-17

7.  Anxiety and Depression in Women with Polycystic Ovary Syndrome.

Authors:  Paweł Dybciak; Ewa Humeniuk; Dorota Raczkiewicz; Jan Krakowiak; Artur Wdowiak; Iwona Bojar
Journal:  Medicina (Kaunas)       Date:  2022-07-16       Impact factor: 2.948

8.  The relationship between some endometrial secretion cytokines and in vitro fertilization.

Authors:  Mohammad Ehsan Rahiminejad; Amirhossein Moaddab; Mehrnoosh Ebrahimi; Soghra Rabiee; Alireza Zamani; Mohammad Ezzati; Alireza Abdollah Shamshirsaz
Journal:  Iran J Reprod Med       Date:  2015-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.